Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Reduce Adhesions Following a Primary Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females 12 years and older undergoing a scheduled primary cesarean section at or after 24 weeks estimated gestational period~Exclusion Criteria:~* Patients transferred from outlying hospitals who expect to undergo repeat C-section at that hospital.~* Patients who have had previous laparotomy~* Patients having a previous laparoscopy demonstrating adhesions of bladder peritoneum or uterine serosa or myometrium to the parietal peritoneum or omentum or bowel to the uterus or parietal peritoneum; or involving pelvic adhesiolysis, enterolysis or other surgery on bowel located in the pelvis, uterine myomectomy , adnexectomy or other adnexal surgery including ovarian cystectomy, tuboplasty, tubal reanastomosis, and removal of endometriosis~* Patients with an adhesion score \> 0 at the time of primary cesarean section~* Patents with chorioamnionitis, appendicitis or infection of other pelvic viscera at the time of primary cesarean section.~* Patients who have taken systemic corticosteroids within 2 weeks of the primary cesarean section. Provided however, patients who have been treated with systemic betamethasone or dexamethasone to promote fetal lung maturity are not excluded~* Patients undergoing tubal sterilization at the time of the primary cesarean section~* Patients with known allergy to hyaluronic acid~* The following criteria are seen as complications or adverse events experienced by the patients in the interval after the puerperium and will therefore exclude patients:~  1. Patient who have had a pelvic inflammatory disease documented by either cervical motion, uterine or adnexal tenderness; and either oral temperature \> 101 degrees or mucopurulent cervical discharge or cervical culture positive for C. trachomatis or N. Gonorrhoeae~ 2. Patients who have pelvic abscess or diverticulitis

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: ACTIVE_COMPARATOR): Patients in this group will receive Seprafilm onto the uterine incision and the anterior midline of the uterus.
- Control Group (Type: NO_INTERVENTION): This arm will be known as the control/no intervention group. This group will not receive Seprafilm or any other adhesion barrier method

Based on this trial design, predict the completion outcome and termination type (if applicable).